ONCTERNAL THERAPEUTICS INC ONCT 深 滬
等待開盤 10-29 09:30:00 美东时间
0.5266
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.5266
- 總市值 155.85万
- 52周最高 13.14
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.5266
- 委 比 0.00%
- 總股本 295.96万
- 歷史最高 211.20
- 量 比 0
- 振 幅 0.00%
- 歷史最低 5.22
- 每 手 1
- 風險率 0.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement
Onconetix, Inc. and Ocuvex Therapeutics, Inc. have mutually terminated their merger agreement, deciding to pursue independent paths. Both companies remain committed to advancing their missions and delivering value to patients. Ocuvex has received its New Jersey state pharmaceutical license and is set to launch Omlonti commercially in the coming weeks. Onconetix and Ocuvex appreciate the collaborative spirit during the merger discussions.
09-26 12:15
Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM
Onconetix, Inc. subsidiary Proteomedix AG has signed a licensing agreement with Immunovia AB, a Swedish pancreatic cancer diagnostics company. The agreement allows Immunovia to use Proteomedix's master cells and intellectual property for producing antibodies related to three biomarkers in the PancreaSure test. Immunovia will pay $700,000 in 2025-2026 and a 3% royalty on net sales from 2026 to 2032. Proteomedix CEO Beat Rheiner expressed pride in ...
09-22 12:00
OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update
OnKure Therapeutics reported Q2 2025 financial results and provided updates on its lead asset, OKI-219, a PI3Kα inhibitor. The company has completed enrollment in the monotherapy and fulvestrant combination arms of the PIKture-01 trial and initiated two new triplet arms for HR+ and HER2+ metastatic breast cancer. Data from the monotherapy and fulvestrant combination arms is expected in Q4 2025. OnKure also advanced its pan-mutant selective PI3Kα ...
08-12 20:05
Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations
Oncternal Therapeutics sold its zilovertamab and ONCT-808 programs to Ho’ola Therapeutics for $3 million upfront, plus up to $65 million in milestone payments. Oncternal will wind down operations under新CEO Craig Jalbert.
07-01 12:00
【天风医药杨松团队|首次覆盖】基石药业-B：迈向管线2.0，ROR1 ADC潜力十足
（来源：市场投研资讯） 基石药业是一家专注于抗肿瘤药物研发的创新驱动型生物医药企业，截至2025 年2月，公司已成功上市4款创新药、获批16项新...
03-12 15:01
Oncternal Therapeutics Announces Workforce Reduction and Executive Changes
Oncternal Therapeutics ( ($ONCT) ) has provided an update. Oncternal Therapeuti...
2024-11-15 06:28
快讯 | Oncternal Therapeutics Inc：四名Oncternal员工将在探索战略选择的过程中以兼职身份继续工作。
Oncternal Therapeutics Inc: Four Oncternal Employees Will Remain in a Part-Time...
2024-11-15 06:09
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Gritstone Bio (NASDAQ:GRTS) shares moved upwards by 42.6% to $0.08 dur...
2024-10-15 20:08
Oncternal Therapeutics Restructures Amid Clinical Setbacks
Oncternal Therapeutics ( ($ONCT) ) has shared an announcement. Oncternal Therap...
2024-09-13 05:18
快讯 | Oncternal Therapeutics：员工减少约10人
Oncternal Therapeutics : Workforce Reduction of About 10 Employees
2024-09-13 05:04
